Story preview
Continue reading on the publisher site for the full article.
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
6
in the last 3 days
First reported
5 days ago
5 outlets since
Countries
5 other outlets reported this story in the last 3 days.
Eli Lilly (NYSE:LLY) stock is in focus as its oral obesity pill and expanding incretin pipeline anchor fresh healthcare-sector headlines today.
Eli Lilly stock follows a USD 870 million collaboration expansion announced on October 5, 2026. Q2 r
Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend through its transformation.